Praxis Precision Medicines
PRAX
291 hedge funds and large institutions have $10.2B invested in Praxis Precision Medicines in 2026 Q1 according to their latest regulatory filings, with 80 funds opening new positions, 121 increasing their positions, 68 reducing their positions, and 33 closing their positions.
142% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 33
78% more repeat investments, than reductions
Existing positions increased: 121 | Existing positions reduced: 68
18% more capital invested
Capital invested by funds: $8.69B → $10.2B (+$1.55B)
16% more funds holding
Funds holding: 250 → 291 (+41)
3.68% less ownership
Funds ownership: 117.84% → 114.16% (-3.7%)
4% less funds holding in top 10
Funds holding in top 10: 24 → 23 (-1)
71% less call options, than puts
Call options by funds: $53.8M | Put options by funds: $187M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
+$377M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$248M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$194M |
| 4 |
BlackRock
New York
|
+$76.2M |
| 5 |
Janus Henderson Group
London,
|
+$67.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$162M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$145M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$120M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$48M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$46.3M |
PRAX Hedge Fund Activity: Q1 2026 in Review
291 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q1 2026, worth a combined $10.2B — up 18% from $8.69B a quarter earlier.
Buyers outnumbered sellers: 80 funds opened new PRAX positions and 33 closed out — a net gain of 47 holders — while 121 added to existing stakes and 68 trimmed.
The largest buyer was Orbis Allan Gray, adding an estimated $377M. The largest seller was Barclays, cutting an estimated $162M.
- 291 institutional investors held Praxis Precision Medicines (PRAX) as of Q1 2026, up from 250 in Q4 2025.
- Funds reported $10.2B of Praxis Precision Medicines stock for Q1 2026, up 18% quarter-over-quarter.
- 80 funds opened new Praxis Precision Medicines positions in Q1 2026 and 33 closed out, a net change of +47 holders.
- The largest Praxis Precision Medicines buyer in Q1 2026 was Orbis Allan Gray, an estimated $377M added.
- The largest Praxis Precision Medicines seller in Q1 2026 was Barclays, an estimated $162M sold.
Based on aggregated 13F filings for Q1 2026.